Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia
L Costanzo, FP Palumbo, G Ardita, PL Antignani… - Journal of Vascular …, 2020 - Elsevier
Abstract The SARS-CoV-2 (COVID-19) is causing a pandemic and potentially fatal disease
of global public health concern. Viral infections are known to be associated with coagulation …
of global public health concern. Viral infections are known to be associated with coagulation …
COVID-19, coagulopathy and venous thromboembolism: more questions than answers
M Marietta, V Coluccio, M Luppi - Internal and emergency medicine, 2020 - Springer
The acute respiratory illnesses caused by severe acquired respiratory syndrome corona
Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people …
Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people …
Viral coagulopathy in patients with COVID-19: treatment and care
COVID-19 has proven to be particularly challenging given the complex pathogenesis of
SARS-CoV-2. Early data have demonstrated how the host response to this novel …
SARS-CoV-2. Early data have demonstrated how the host response to this novel …
Anticoagulation in hospitalized patients with COVID-19
L Baumann Kreuziger, M Sholzberg… - Blood, The Journal of …, 2022 - ashpublications.org
Abstract Coronavirus disease-19 (COVID-19) includes a thromboinflammatory syndrome
that may manifest with microvascular and macrovascular thrombosis. Patients with COVID …
that may manifest with microvascular and macrovascular thrombosis. Patients with COVID …
The versatile heparin in COVID‐19
J Thachil - Journal of Thrombosis and Haemostasis, 2020 - jthjournal.org
Coagulopathy in coronavirus infection has been shown to be associated with high mortality
with high D-dimers being a particularly important marker for the coagulopathy. 1 In the latest …
with high D-dimers being a particularly important marker for the coagulopathy. 1 In the latest …
Fibrinolysis shutdown and thrombosis in severe COVID-19
The coagulopathy associated with COVID-19 has emerged as a key driver of morbidity and
mortality, especially in patients with severe disease. There is mounting evidence that a …
mortality, especially in patients with severe disease. There is mounting evidence that a …
Non‐severe COVID‐19 is associated with endothelial damage and hypercoagulability despite pharmacological thromboprophylaxis
S Kelliher, L Weiss, S Cullivan… - … of Thrombosis and …, 2022 - Wiley Online Library
Background Hypercoagulability and endothelial dysfunction are hallmarks of coronavirus
disease 2019 (COVID‐19) and appear to predict disease severity. A high incidence of …
disease 2019 (COVID‐19) and appear to predict disease severity. A high incidence of …
COVID-19 associated coagulopathy and thrombotic complications
ZT Mezalek, H Khibri, W Ammouri… - Clinical and Applied …, 2020 - journals.sagepub.com
The SARS-CoV-2 virus caused a global pandemic within weeks, causing hundreds of
thousands of people infected. Many patients with severe COVID-19 present with coagulation …
thousands of people infected. Many patients with severe COVID-19 present with coagulation …
Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: a call to …
V Pavoni, L Gianesello, M Pazzi, C Stera, T Meconi… - Thrombosis research, 2020 - Elsevier
Background Critically ill COVID-19 patients have a clear pattern of inflammation and
hypercoagulable state. The main aim of the study was to evaluate the outcome of severe …
hypercoagulable state. The main aim of the study was to evaluate the outcome of severe …
COVID‐19 and coagulopathy
M Sarkar, IV Madabhavi, PN Quy… - The clinical …, 2021 - Wiley Online Library
The SARS‐CoV‐2 is a new coronavirus responsible for the COVID‐19 disease and has
caused the pandemic worldwide. A large number of cases have overwhelmed the …
caused the pandemic worldwide. A large number of cases have overwhelmed the …